{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T06:11:20Z","timestamp":1697004680966},"reference-count":18,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2007,3,7]],"date-time":"2007-03-07T00:00:00Z","timestamp":1173225600000},"content-version":"vor","delay-in-days":6,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["HIV Medicine"],"published-print":{"date-parts":[[2007,3]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Highly active antiretroviral therapy (HAART) has dramatically changed the prognosis of HIV disease, even in terminally ill patients. Although these patients may survive many years after the diagnosis of AIDS if treated with HAART, some still die during treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A retrospective study in a cohort of 481 HIV\u2010infected patients treated with HAART between January 1998 and December 2005 was conducted to compare subgroups of long\u2010term survivors (LTSs) and patients who died during treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 48 patients survived for more than 72 months (mean 83.8\u00b1standard deviation 5.6 months). Thirty patients died during treatment (mean 35.3\u00b125.0 months), of whom nine died from non\u2010AIDS\u2010related causes, 18 died from AIDS\u2010related causes, and three died as a result of HAART toxicity. Although LTSs were significantly (<jats:italic>P=<\/jats:italic>0.015) younger at HAART initiation, age below 40 years was not a predictor of long\u2010term survival. The subgroups did not differ in the proportion of clinical AIDS cases at HAART initiation, in the prevalence of hepatitic C virus (HCV) coinfection, or in pretreatment and end\u2010of\u2010follow\u2010up CD4 cell counts. In contrast, the viral load achieved during treatment was lower in the survivors (<jats:italic>P=<\/jats:italic>0.03), as was the prevalence of hepatitis B virus (HBV) coinfection (<jats:italic>P=<\/jats:italic>0.03). Usage of either protease inhibitor (PI)\u2010containing regimens [odds ratio (OR) 9.0, 95% confidence interval (CI) 2.2\u201335.98, <jats:italic>P<\/jats:italic>&lt;0.001] or all three drug classes simultaneously (OR 7.4, 95% CI 2.2\u201325.1, <jats:italic>P<\/jats:italic>&lt;0.001) was associated with long\u2010term survival. Drug holidays incorporated in structured treatment interruption (STI) were also associated with a good prognosis (OR 14.9, 95% CI 2.9\u201375.6, <jats:italic>P<\/jats:italic>&lt;0.001).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Long\u2010term survival was associated with PI\u2010based HAART regimens and lower viraemia, but not with the immunological status either at baseline or at the end of follow up. STI when CD4 counts reach 350\u2003cells\/\u03bcL, along with undetectable viraemia, was a strong predictor of long\u2010term survival.<\/jats:p><\/jats:sec>","DOI":"10.1111\/j.1468-1293.2007.00429.x","type":"journal-article","created":{"date-parts":[[2007,3,7]],"date-time":"2007-03-07T19:19:42Z","timestamp":1173295182000},"page":"75-79","source":"Crossref","is-referenced-by-count":6,"title":["Long\u2010term survival of HIV\u2010infected patients treated with highly active antiretroviral therapy in Serbia and Montenegro"],"prefix":"10.1111","volume":"8","author":[{"given":"DO","family":"Jevtovi\u0107","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D","family":"Salemovi\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Ranin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I","family":"Pe\u0161i\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"\u017derjav","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O","family":"Djurkovi\u0107\u2010Djakovi\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2007,3,7]]},"reference":[{"key":"e_1_2_6_2_2","first-page":"378","article-title":"Long\u2010term effectiveness of potent antiretroviral therapy in preventing AIDS and death","volume":"366","author":"Sterne JAC","year":"2005","journal-title":"a prospective cohort study"},{"key":"e_1_2_6_3_2","first-page":"659","article-title":"Improved survival among HIV\u2010infected patients after initiation of triple\u2010drug antiretroviral regimens","volume":"160","author":"Hogg RS","year":"1999","journal-title":"Can Med Assoc J"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-135-1-200107030-00005"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1097\/00042560-199904010-00008"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-139-10-200311180-00008"},{"key":"e_1_2_6_7_2","first-page":"249","article-title":"Increasing survival time after AIDS in Italy","volume":"13","author":"Pezzotti P","year":"1999","journal-title":"the role of new combination antiretroviral therapies"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199803263381301"},{"key":"e_1_2_6_9_2","first-page":"119","article-title":"Prognosis of HIV\u20101\u2010infected patients starting highly active antiretroviral therapy","volume":"360","author":"Egger M","year":"2002","journal-title":"a collaborative analysis of prospective studies"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1086\/343862"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1097\/00126334-200204010-00009"},{"key":"e_1_2_6_12_2","first-page":"1","article-title":"1993 CDC revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults","volume":"41","year":"1992","journal-title":"Morbidity and Mortality Weekly Report"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2005.07.006"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-133-6-200009190-00007"},{"key":"e_1_2_6_15_2","first-page":"67","article-title":"Deaths in the era of HAART","volume":"20","author":"Sabin CA","year":"2006","journal-title":"contribution of late presentation, treatment exposure, resistance and abnormal laboratory markers"},{"key":"e_1_2_6_16_2","first-page":"2195","article-title":"Drug\u2010resistance genotyping in HIV\u20101 therapy","volume":"353","author":"Durant J","year":"1999","journal-title":"the VIRADAPT randomised controlled trial"},{"key":"e_1_2_6_17_2","unstructured":"El\u2010SadrW NeatonJ SMART Study Investigators.Episodic CD4\u2010guided use of ART is inferior to continuous therapy: Results of the SMART study.13th Conference on Retroviruses and Opportunistic Infections. Denver CO February 2006 [Abstract 106LB]."},{"key":"e_1_2_6_18_2","first-page":"439","article-title":"Effect of prolonged discontinuation of successful antiretroviral therapy on CD4\u2003T cells","volume":"18","author":"Maggiolo F","year":"2004","journal-title":"a controlled, prospective trial"},{"key":"e_1_2_6_19_2","first-page":"287","article-title":"CD4 cell\u2010monitored treatment interruption in patients with a CD4 cell count >500 \u00d7 106\u2003cells\/l","volume":"19","author":"International Study Group on CD4\u2010monitored Treatment Interruptions.","year":"2005","journal-title":"AIDS"}],"container-title":["HIV Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1468-1293.2007.00429.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1468-1293.2007.00429.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T02:18:19Z","timestamp":1696904299000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1468-1293.2007.00429.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,3]]},"references-count":18,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2007,3]]}},"alternative-id":["10.1111\/j.1468-1293.2007.00429.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1468-1293.2007.00429.x","archive":["Portico"],"relation":{},"ISSN":["1464-2662","1468-1293"],"issn-type":[{"value":"1464-2662","type":"print"},{"value":"1468-1293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,3]]}}}